MedTrace Logo

Pregabalin for the Treatment of Vulvodynia

NCT00853229 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-07-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether pregabalin is effective in the treatment of vulvodynia.

Conditions

  • Vulvodynia
  • Vulvar Vestibulitis

Interventions

DRUG

pregabalin

pregabalin 150mg twice daily for 4 weeks

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Beri M Ridgeway, MD · The Cleveland Clinic

  • Matthew D Barber, MD, MHS · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853229 on ClinicalTrials.gov